Past performance does not predict future results. Informational only, not investment advice.
Fukushima Ryan (CEO, Data at Tempus AI, Inc.) reported an open-market sale of 41,095 shares of TEM at an average $49.61, roughly $2,038,723, in a Form 4 filed 2026-08-20.
LEFKOFSKY ERIC P (CEO and Chairman at Tempus AI, Inc.) reported an open-market sale of 132,591 shares of TEM at an average $49.61, roughly $6,577,840, in a Form 4 filed 2026-08-20.
Bartolucci Ryan M (Chief Accounting Officer at Tempus AI, Inc.) reported an open-market sale of 6,175 shares of TEM at an average $49.61, roughly $306,342, in a Form 4 filed 2026-08-20.
Tempus AI will acquire Personalis, which is the gene sequencing technology underlying Moderna's cancer vaccine program. With Moderna's recent 200% gain validating the cancer vaccine opportunity, Tempus is undervalued relative to the deal upside and can capture further upside from the personalized oncology tailwind.
Tempus owns continuously updated proprietary clinical datasets and physician interaction workflows that are essential for training medical AI models. The company is positioned as a strategic AI data supplier in healthcare, with the data business representing a multi-billion dollar opportunity.
End of results.